| Title |
-
en
STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation
|
| Creator |
|
| Accessrights |
metadata only access |
| Subject |
-
Other
en
adjuvants
-
Other
en
pharmaceutic
-
Other
en
immunotherapy
-
Other
en
killer cells
-
Other
en
natural
-
Other
en
melanoma
-
Other
en
drug therapy
-
Other
en
combination
-
NDC
499
|
| Description |
-
Abstract
en
Background Resistance to an immune checkpoint inhibitor (ICI) is a major obstacle in cancer immunotherapy. The causes of ICI resistance include major histocompatibility complex (MHC)/histocompatibility locus antigen (HLA) class I loss, neoantigen loss, and incomplete antigen presentation. Elimination by natural killer (NK) cells would be expected to be an effective strategy for the treatment of these ICI-resistant tumors. We previously demonstrated that a lipid nanoparticle containing a stimulator of an interferon gene (STING) agonist (STING-LNP) efficiently induced antitumor activity via the activation of NK cells. Thus, we evaluated the potential of reducing ICI resistance by STING-LNPs. Methods Lung metastasis of a B16-F10 mouse melanoma was used as an anti-programmed cell death 1 (anti-PD-1)-resistant mouse model. The mice were intravenously injected with the STING-LNP and the mechanism responsible for the improvement of anti-PD-1 resistance by the STING-LNPs was analyzed by RT-qPCR and flow cytometry. The dynamics of STING-LNP were also investigated. Results Although anti-PD-1 monotherapy failed to induce an antitumor effect, the combination of the STING-LNP and anti-PD-1 exerted a synergistic antitumor effect. Our results indicate that the STING-LNP treatment significantly increased the expression of CD3, CD4, NK1.1, PD-1 and interferon (IFN)-gamma in lung metastases. This change appears to be initiated by the type I IFN produced by liver macrophages that contain the internalized STING-LNPs, leading to the systemic activation of NK cells that express PD-1. The activated NK cells appeared to produce IFN-gamma, resulting in an increase in the expression of the PD ligand 1 (PD-L1) in cancer cells, thus leading to a synergistic antitumor effect when anti-PD-1 is administered. Conclusions We provide a demonstration to show that a STING-LNP treatment can overcome PD-1 resistance in a B16-F10 lung metastasis model. The mechanism responsible for this indicates that NK cells are activated by stimulating the STING pathway which, in turn, induced the expression of PD-L1 on cancer cells. Based on the findings reported herein, the STING-LNP represents a promising candidate for use in combination therapy with anti-PD-1-resistant tumors.
|
| Publisher |
en
BMJ Publishing Group
|
| Date |
|
| Language |
|
| Resource Type |
journal article |
| Version Type |
NA |
| Identifier |
HDL
http://hdl.handle.net/2115/83019
|
| Relation |
-
isIdenticalTo
DOI
https://doi.org/10.1136/jitc-2021-002852
|
| Journal |
-
en
Journal for immunotherapy of cancer
-
Volume Number9
Issue Number7
Page Starte002852
|
| Oaidate |
2023-07-26 |
